CA-BITMOVIN
1.10.2020 12:02:09 CEST | Business Wire | Press release
Is the party over for video streaming companies? While COVID-19 has impacted businesses of all types and sizes, the streaming/OTT industry has seen a major impact. With more consumers staying home and utilizing streaming services, video consumption has skyrocketed, but so have costs. Bitmovin, a leading provider of video infrastructure for digital media companies around the world, today revealed the results of its fourth annual “Video Developer Report” showcasing the current state of the video/streaming/OTT industry along with challenges being faced by video developers and the latest trends.
The entire study can be viewed here
Key findings include:
Top Challenge – Reducing Costs
Bitmovin recognizes this year has ushered in an unparalleled number of challenges and unique opportunities for all businesses within the industry. The results showed the top challenge among respondents was reducing costs, replacing last year’s top concern of complex technology such as ‘live low latency.” Despite the majority of participants holding technical roles, over 51% of respondents indicated that cost control for such things as bandwidth and storage is their biggest challenge. The results are clear that many in the industry believe that video streaming services need to focus on cost optimization in order to survive.
Greatest Opportunity for Innovation – Live Streaming at Scale & Viewer Engagement
Sometimes a crisis is the best instigator of innovation because people are searching for solutions. Many streaming media industry innovations were already in progress before COVID-19, but the crisis has certainly sped up the adoption of some specific ones.
Mastering live streaming at scale is not an easy job and while it is a top challenge in the report, respondents also see this as the greatest opportunity for innovation. Viewer engagement can be complex as well, considering the different kinds of viewers that use a service and need to be engaged in different ways. “Recommendations” and “personalizations” will play an even great role moving forward, as developers are tasked with new ways of retaining viewers. We can also expect innovative ways streaming services and providers find to put on compelling content, whether live sports, concerts, musicals, or shows.
“As the streaming/OTT industry continues to rapidly expand, new challenges and opportunities will develop. Bitmovin is proud to be on the front-lines of the industry each day and this year’s study shows that even with growth there is a need for deep reflection on how money is spent and where to put assets and talent,” said Stefan Lederer, CEO of Bitmovin. “In today’s COVID world, there is huge volatility that is accompanied by large demand. The industry players that best recognize the changing technological and financial landscape will be the ones that not only survive, but thrive.”
Survey Methodology
For the fourth consecutive year, Bitmovin has conducted its Annual Video Developer Survey between June 29 - August 9, 2020. The number of participants in the Survey and countries represented similarly reflect this global surge in demand for streaming. Bitmovin surveyed a sample set of 792 video developers and industry experts from 87 countries--participation was up dramatically by 46% from 2019. Consistent with years past, demographics such as industry, company size, and job titles were predominantly in three key industry categories: broadcasters, integrators, and OTT streaming services.
About Bitmovin:
Built for technical professionals in the OTT video market, Bitmovin’s software solutions help you optimize customer operations and reduce time-to-market, resulting in the best viewer experience imaginable. This is achieved through our device reach, flexible and scalable integration, and commitment to supporting our customers. Learn more at www.bitmovin.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201001005071/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom